Do analysts prefer ADTX or ARAV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ADTX or ARAV?

Aravive has lower revenue, but higher earnings than Aditxt. Aravive is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.12 -$41.71M -$100.79 thousand N/A Aravive N/A N/A N/A -$0.90 N/A

Is ADTX or ARAV more profitable?

Aravive has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aravive's return on equity of 0.00% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Aravive N/A N/A N/A

Which has better valuation & earnings, AIMDW or ARAV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $18.11K N/A N/A N/A N/A Aravive N/A N/A N/A -$0.90 N/A

Is AIMDW or ARAV more profitable?

Company Net Margins Return on Equity Return on Assets Ainos N/A N/A N/A Aravive N/A N/A N/A

Which has preferable valuation & earnings, ARAV or ALVOW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Alvotech $559.42M N/A N/A N/A N/A

Is ARAV or ALVOW more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Alvotech N/A N/A N/A

Which has higher earnings & valuation, ARAV or ACABW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A

Is ARAV or ACABW more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Atlantic Coastal Acquisition Corp. II N/A N/A N/A

Which has stronger earnings & valuation, ARAV or BFRIW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Biofrontera $43.20M N/A N/A N/A N/A

Is ARAV or BFRIW more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Biofrontera N/A N/A N/A

Aravive (ARAV) Competitors

$0.04 0.00 (0.00%)

As of 06/25/2026

Compare

ARAV vs. ADTX, AIMDW, ALVOW, ACABW, and BFRIW

Should you buy Aravive stock or one of its competitors? MarketBeat compares Aravive with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aravive include Aditxt (ADTX), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Aravive compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Aravive has lower revenue, but higher earnings than Aditxt. Aravive is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.12	-$41.71M	-$100.79 thousand	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aravive has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aravive's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Aravive	N/A	N/A	N/A

In the previous week, Aditxt had 7 more articles in the media than Aravive. MarketBeat recorded 7 mentions for Aditxt and 0 mentions for Aravive. Aditxt's average media sentiment score of 0.36 beat Aravive's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Neutral
Aravive	Neutral

Summary

Aravive beats Aditxt on 6 of the 11 factors compared between the two stocks.

How does Aravive compare to Ainos?

Ainos (NASDAQ:AIMDW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$18.11K	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

In the previous week, Ainos had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Ainos and 0 mentions for Aravive. Ainos' average media sentiment score of 1.43 beat Aravive's score of 0.00 indicating that Ainos is being referred to more favorably in the media.

Company	Overall Sentiment
Ainos	Positive
Aravive	Neutral

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ainos beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Alvotech?

Aravive (NASDAQ:ARAV) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Alvotech	$559.42M	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Alvotech	N/A	N/A	N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Alvotech had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Alvotech and 0 mentions for Aravive. Alvotech's average media sentiment score of 0.93 beat Aravive's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Alvotech	Positive

Summary

Alvotech beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Atlantic Coastal Acquisition Corp. II?

Aravive (NASDAQ:ARAV) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A

In the previous week, Aravive's average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.

Company	Overall Sentiment
Aravive	Neutral
Atlantic Coastal Acquisition Corp. II	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Summary

Aravive beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Aravive compare to Biofrontera?

Aravive (NASDAQ:ARAV) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Biofrontera	$43.20M	N/A	N/A	N/A	N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Biofrontera	N/A	N/A	N/A

In the previous week, Biofrontera had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Aravive. Biofrontera's average media sentiment score of 1.44 beat Aravive's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Biofrontera	Positive

Summary

Biofrontera beats Aravive on 3 of the 5 factors compared between the two stocks.

Get Aravive News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAV vs. The Competition

Export

Metric	Aravive	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$3.55B	$6.70B	$12.23B
Dividend Yield	N/A	2.25%	2.67%	6.12%
P/E Ratio	-0.04	21.56	25.76	24.17
Price / Sales	N/A	336.67	555.64	99.96
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	N/A	8.34	10.77	6.35
Net Income	N/A	$23.91M	$3.57B	$337.63M
7 Day Performance	N/A	6.85%	3.17%	0.43%
1 Month Performance	N/A	4.25%	1.86%	0.14%
1 Year Performance	N/A	65.92%	34.39%	27.64%

Aravive Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ADTX Aditxt	0.9904 of 5 stars	$0.00 -59.6%	N/A	-100.0%	$0.00	N/A	N/A	60	Analyst Downgrade Short Interest Increase Gap Up High Trading Volume
AIMDW Ainos	N/A	$0.13 -12.4%	N/A	-20.5%	$0.00	$18.11K	N/A	40	Short Interest Decrease Gap Down
ALVOW Alvotech	N/A	$0.33 flat	N/A	-90.0%	$0.00	$559.42M	N/A	4	News Coverage Positive News Gap Up
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAV) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aravive (ARAV) Competitors